NewsBenzinga뉴로크린 바이오사이언스, 새로운 설문조사 결과 발표···성인 지연성 운동장애 환자, 잉그레자 캡슐 치료 시작 후 직장·학교 생활 방해 감소 보고 뉴로크린 바이오사이언스, 새로운 설문조사 결과 발표···성인 지연성 운동장애 환자, 잉그레자 캡슐 치료 시작 후 직장·학교 생활 방해 감소 보고 Benzinga 2026.11.05 13:37 (GMT+0) Open on Benzinga Other news Canaccord Genuity Maintains Buy on Belite Bio, Raises Price Target to $314 Applied Optoelectronics Stock Sinks Amid AI Outlook Fears Canaccord Genuity Maintains Buy on Enovix, Lowers Price Target to $2.5 Canaccord Genuity Maintains Buy on Intuitive Machines, Lowers Price Target to $38 'A Zelle representative said that a technical issue on its platform originated with Chase' -NBC Report Canaccord Genuity Maintains Buy on Nektar Therapeutics, Lowers Price Target to $149
'A Zelle representative said that a technical issue on its platform originated with Chase' -NBC Report